Genomtec (WAR:GMT) ROCE % : -58.46% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Genomtec ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genomtec's annualized ROCE % for the quarter that ended in Dec. 2023 was -58.46%.

Genomtec ROCE % Historical Data

The historical data trend for Genomtec's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomtec ROCE % Chart

Genomtec Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-149.75

-219.46

-142.93

-210.83

-80.07

Genomtec Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial											-330.10	-96.00	-54.88	-58.66	-58.46

Genomtec ROCE % Calculation

Genomtec's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-8.912	/	( ( (11.756 - 2.324)	+	(15.972 - 3.144) )	/ 2 )
	=	-8.912	/	( (9.432	+	12.828)	/ 2 )
	=	-8.912	/	11.13
	=	-80.07 %

Genomtec's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-8.74	/	( ( (19.394 - 2.323)	+	(15.972 - 3.144) )	/ 2 )
	=	-8.74	/	( ( 17.071	+	12.828 )	/ 2 )
	=	-8.74	/	14.9495
	=	-58.46 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Genomtec (WAR:GMT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genomtec ROCE % Related Terms

Thank you for viewing the detailed overview of Genomtec's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genomtec (WAR:GMT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Genomtec SA (WAR:GMT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

4VI:Germany

Address

ul. Stab?owicka 147, PORT Building 2, Wroclaw, POL, 54-066

Website

http://www.genomtec.com

Genomtec SA is an innovative technology company which works in the area of ?? molecular diagnostics. It is a manufacturer of mobile molecular analyzers. The device are designed to identify pathogens including viruses, bacteria, and fungi by amplifying and detecting specific DNA and RNA fragments.

Genomtec (WAR:GMT) Headlines

No Headlines